Patented platform uses cell-free DNA analysis and machine learning to detect cancer early and identify tissue of origin from ...

In a significant step towards advancing early cancer detection in India, Strand Life Sciences, a subsidiary of Reliance ...

Reliance's Strand Life Sciences secures Indian patent for blood-based early cancer detection technology ...

We're on the cusp of a new era in cancer care – one that could dramatically improve survival and quality of life.

Reliance’s Strand Life Sciences patents a blood-based technology for early cancer detection, enhancing accuracy and accessibility.

Esophageal cancer, which is cancer of the swallowing tube, has only a 22.2% five-year relative survival rate, but early ...

For patients here in the commonwealth and across the country, we’re on the cusp of a new era in cancer care — one that could ...

A machine learning program that identified patients overdue for colorectal cancer screening helped increase screening rates ...

Reliance's Strand Life Sciences patents a liquid biopsy platform for early cancer detection using AI and cfDNA analysis in ...

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common ...